Open AccessSunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists
Author(s) -
Laurence Klotz
Publication year - 2012
Publication title -
canadian urological association journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.477
H-Index - 38
eISSN - 1920-1214
pISSN - 1911-6470
DOI - 10.5489/cuaj.70
Subject(s) - sunitinib , sorafenib , medicine , kidney cancer , systemic therapy , cancer , oncology , pharmacology , breast cancer , hepatocellular carcinoma